Physician profile
John M Mcdaniel
NPI 1932294204
$1,898.16
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $593 · 2021: $219 · 2022: $14.17 · 2023: $24.62 · 2024: $26.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $392.10 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $322.82 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $264.69 | 2019-2020 | |
| Lilly USA, LLC | $177.81 | 2019-2021 | |
| Pfizer INC. | $146.57 | 2019-2023 | |
| Abbvie INC. | $99.65 | 2019-2021 | |
| Astellas Pharma US INC | $77.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.69 | 2019-2021 | |
| Eisai INC. | $43.39 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $42.64 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.32 | 2019-2020 | |
| Allergan, INC. | $31.93 | 2019-2020 | |
| Amgen INC. | $27.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $24.28 | 2021 | |
| Amarin Pharma, INC. | $19.67 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $19.37 | 2019 | |
| Tris Pharma INC | $17.13 | 2019 | |
| Ibsa Pharma INC. | $16.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.38 | 2019 | |
| Sanofi Pasteur INC. | $15.33 | 2019 | |
| Merck Sharp & Dohme LLC | $12.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.34 | 2019 | |
| Horizon Therapeutics Plc | $12.32 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.51 | 2020 | |
| Glaxosmithkline, LLC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.